GM-CSF对MUC1基因疫苗抑制乳腺癌生长的增强作用

目的 :观察GM CSF有无增强MUC1基因疫苗对EMT6乳腺癌生长的特异性抑制作用。方法 :采用股四头肌肌肉注射法 ,将构建的MUC1基因疫苗pcDNA3.1 MUC1免疫雌性BALB/c小鼠 ,每 3wk 1次 ,共 3次。每次基因免疫后 1、3、5d ,皮下注射GM CSF 10 0 μL(1μg/ 10 0 μL)。最后 1次基因免疫后第 3周 ,接种表达MUC1的EMT6小鼠乳腺癌细胞。两周后观察、记录肿瘤的生长情况。于肿瘤细胞接种后第 4 3天 ,处死全部动物 ,称量肿瘤的质量。用 4h51Cr释放法检测小鼠脾特异性CTL的杀伤活性。结果 :接种肿瘤细胞后 4 3d ,MUC1基因疫苗加GM CSF组、MUC1基因疫苗组、pcDNA3.1加GM CSF组及pcDNA3.1组 ,EMT6肿瘤的大小依次为 (135± 33.8)mm3 、(2 5 0± 34.3)mm3 、(5 6 8± 4 3.6 )mm3 和 (5 96± 4 8.2 )mm3 ;平均瘤质量 (g)依次为 (0 .81± 0 .4 2 )g、(1.2 3± 0 .4 1)g、(2 .30± 0 .4 8)g及 (2 .2 8± 0 .5 8)g。与对照组相比较 ,MUC1基因疫苗组EMT6肿瘤的生长受到明显抑制 (P <0 .0 5 ) ;与单独MUC1基因疫苗组相比较 ,MUC1基因疫苗加GM CSF组抗肿瘤生长的作用有显著差异 (P <0 .0 5 )。在效靶比为 10 0∶1、5 0∶1、2 5∶1和 12 .5∶1时 ,MUC1基因疫苗加GM CSF组特异性CTL对EMT6靶细胞的杀伤率 ,依次为 6 8.5 %、 5 3.4 %     

NaoXinQing, an anti-stroke herbal medicine, reduces hydrogen peroxide-induced injury in NG108-15 cells

NaoXinQing (NXQ) is a patented and approved drug of Traditional Chinese Medicine that has been used for years for the treatment of syndrome of apoplexy, but the underlying mechanism remains unclear. The present study is designed to investigate the effects of NXQ on hydrogen peroxide (H(2)O(2))-induced cell damage in NG108-15 cells. Exposure to H(2)O(2) induces apoptosis-like cell injury. Preincubation of cells with NXQ alleviated H(2)O(2)-induced cell injury and apoptosis. This herb medicine also improves redox imbalance in cells under the exposure of H(2)O(2) as indicated by the attenuation in the reduction of activities of intracellular endogenous antioxidants, glutathione and glutathione peroxidase as well as catalase, and by the decrease in the leak of lactate dehydrogenase and the accumulation of malondialdehyde. These results indicate that NXQ significantly protects NG108-15 cells against H(2)O(2) challenge by improving redox imbalance and inhibiting apoptosis, which might represent mechanisms underlying its potential usage in the prevention and treatment of syndrome of apoplexy.     

优化的贴片型测量探头及其生物医学应用研究

采用时域有限差分（FDTD）法结合遗传算法（GA）优化设计了适用于浅表生物组织高频测量的宽带同轴贴片探头，并用该探头测量了人体背部1～7GHz频带内的反射特性。优化设计出的圆形同轴贴片探头具有轴对称特点，辐射近场在生物组织中透人深、反射系数的频率响应特性好。所获得的人体背部反射特性的测量结果将为背部浅表组织电特性的重建提供有利的依据。     

Dihydrofolate reductase from Kaposi's sarcoma-associated herpesvirus

Kaposi's sarcoma-associated herpesvirus (KSHV) is the first human virus known to encode dihydrofolate reductase (DHFR), an enzyme required for nucleotide and methionine biosynthesis. We have studied the purified KSHV-DHFR enzyme in vitro and analyzed its expression in cultured B-cell lines derived from primary effusion lymphoma (PEL), an AIDS-associated malignancy. The amino acid sequence of KSHV-DHFR is most similar to human DHFR (hDHFR), but the viral enzyme contains an additional 23 amino acids at the carboxyl-terminus. The viral DHFR, overexpressed and purified from E. coli, was catalytically active in vitro. The K(m) of KSHV-DHFR for dihydrofolate (FH(2)) was 2.4 microM, which is significantly higher than the K(m) of recombinant hDHFR (rhDHFR) for FH(2) (390 nM). K(m) values for NADPH were similar for the two enzymes, about 1 microM. KSHV-DHFR was inhibited by folate antagonists such as methotrexate (K(i): 200 pM), aminopterin (K(i): 610 pM), pyrimethamine (K(i): 29 nM), trimethoprim (K(i): 2.3 microM), and piritrexim (K(i): 3.9 nM). In all cases, K(i) values for these folate antagonists were higher for KSHV-DHFR than for rhDHFR. The viral enzyme was expressed at levels two- to tenfold higher than hDHFR in PEL cell lines as an early lytic cycle gene. KSHV-DHFR mRNA and protein appeared from 6 to 24 h after chemical induction of the KSHV lytic cycle. Epitope-tagged KSHV-DHFR and rhDHFR both localized to the nucleus of transfected cells, while other KSHV nucleotide metabolism genes localized to the cytoplasm. DHFR activity was not essential for viral replication in cultured PEL cells. Since hDHFR was not detectable in peripheral blood mononuclear cells (PBMCs), KSHV-DHFR may function to provide increased DHFR activity in vivo in infected cells that have little or none of their own enzyme.     

严重会阴部挫裂伤治疗方案探讨

目的探讨会阴部严重挫裂伤治疗的合理方案，提高治疗质量。方法通过回顾我院收治的18例会阴部严重挫裂伤病例的治疗过程，总结与分析了这类损伤不宜Ⅰ期修复的原因和结肠造瘘术在治疗中的作用。结果本组18例会阴部严重挫裂伤，均在早期清创缝合修复，后因感染，同时并发不同程度、不同范围的皮肤坏死而造成缺损和伤口裂开。均需再次清创、皮瓣转移和植皮予以修复。在此过程中，采用结肠造瘘术来控制创面感染和预防创面继发感染，收到了良好效果。结论严重会阴部挫裂伤创面的早期治疗，特别是污染重、挫伤重、损伤范围大的，均不宜Ⅰ期修复。早期行结肠造瘘术对预防和控制会阴部创面感染能起到重要的作用。     

CD40L表达在异基因造血干细胞移植中GVHD发生的意义

目的：初步探讨在异基因造血干细胞移植（HSCT）中发生移植物抗宿主病（GVHD）患者DC40L表达的变化以及意义。方法：HSCT治疗重型β-地中海贫血（n=12）和遗传性溶血性贫血（n=1）成功植入的儿童患者，其中脐血移植（UCBT）8例，异基因外周血造血干细胞移植(allo-PBSCT)5例，在移植前、移植后发生GVHD时采用流式细胞仪检测和比较外周血中CD40L和CD40的表达。结果：3例UCBT无GVHD，其余均发生了Ⅰ-Ⅳ度急性GVHD。急性GVHD发生时CD4^ CD40L^ 和CD8^ CD40LT细胞表达明显升高，allo-PBSCT者更明显；慢性GVHD发生时患者的CD40L^ 、CD25^ 和CD69^ 在CD4^ 和CD8^ T细胞上的表达亦增加。CD19^ CD40^ B细胞的表达在UCBT和allo-PBSCT的3个月内则一直处于低于正常的水平。结论：CD40L高表达与GVHD的发生相关，提示CD40-CD40L共刺激途径在GVHD的发生中可能起着重要作用。     

妥布霉素伤用凝胶的体外抗菌作用研究

观察妥布霉素伤用凝胶的体外抗菌活性 ,为临床应用提供试验依据。采用平皿二倍稀释法测定了妥布霉素伤用凝胶对临床分离的 12 0株临床常见的革兰氏阳性及革兰氏阴性菌的体外抗菌作用。以对青霉素敏感的金葡菌、表葡菌、对庆大霉素敏感的大肠杆菌、敏感绿脓杆菌的作用为最强 ,MIC50 均为 0 2 5mg/L。妥布霉素伤用凝胶抗菌谱较广 ,对试验中的革兰氏阳性及革兰氏阴性菌均具有较强的杀灭或抑制作用 ,显示出较好的抗菌活性。     

腺病毒载体介导bcl-2基因转染在离体和在体状态下对损伤运动神经元的保护作用

本文目的在于观察携带 bcl-2基因的重组腺病毒 (Ad/ s-bcl-2 )在离体和在体条件下对损伤运动神经元的保护作用。采用培养脊髓运动神经元的谷氨酸损伤模型和大鼠坐骨神经切断损伤模型 ,评价重组 bcl-2腺病毒对损伤运动神经元的影响。指标是bcl-2原位杂交和免疫组化反应、台盼蓝拒染法检测培养神经元存活、TU NEL 阳性神经元计数以及脊髓运动神经元 ACh E反应。结果 :(1) Ad/ s-bcl-2可转染离体和在体脊髓运动神经元并使其过表达 bcl-2。 (2 )过表达 bcl-2可延长培养神经元的生存时间。(3 )过表达 bcl-2可显著地减少谷氨酸诱导的原代培养脊髓运动神经元的凋亡以及坐骨神经切断损伤诱导的脊髓运动神经元的凋亡。 (4 )过表达 bcl-2可显著地缓解坐骨神经损伤诱导的神经元内 ACh E的活性降低 ,并加速其恢复。本研究结果提示 :腺病毒载体中介 bcl-2基因转染对离体和在体损伤的运动神经元均具有保护作用     

Resolving the composite trait of hypertension into its pharmacogenetic determinants by acute pharmacological modulation of blood pressure regulatory systems

Acute pharmacogenetic analysis was carried out in an intercross F2 population derived from Prague hypertensive-hypertriglyceridemic and Lewis rats. Quantitative trait loci (QTL) mapping was performed for baseline blood pressure (BP) and for BP after blockade of the renin-angiotensin system by losartan, of the sympathetic nervous system (SNS) by pentolinium, and of the nitric oxide system by N(G)-nitro- L-arginine methyl ester. Two significant loci for baseline BP were found on chromosome (Chr) 3 (logarithm of likelihood, LOD, 3.8) and Chr 5 (LOD 3.6), and one suggestive locus on Chr 1 (LOD 2.7). The QTL on Chr 3 persisted after treatment with the three agents while the QTL on Chr 5 and Chr 1 disappeared after pentolinium administration. This suggests independence of the locus on Chr 3 from each acute BP regulatory system examined, whereas the loci on Chr 5 and Chr 1 appeared to be controlled mainly by the SNS. Although not apparent at baseline, a significant locus appeared on Chr 8 (LOD 7.0) after blockade of the SNS, and NO system blockade led to the appearance of a new QTL on Chr 1 (LOD 3.6), indicating the contribution of the inhibited systems to these loci. Pharmacogenetic dissection of the BP trait is a powerful tool to unravel the underlying physiological mechanisms of QTL affecting baseline BP and to identify specific QTL for the response to drugs. This pharmocogenetic approach enabled us to determine the main causative acute BP regulatory systems and should lead to better selection of suitable antihypertensive drugs for individual patients.